ALOCRIL Drug Patent Profile

When do Alocril patents expire, and what generic alternatives are available?

Alocril is a drug marketed by Allergan and is included in one NDA.

The generic ingredient in ALOCRIL is nedocromil sodium. There are three drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the nedocromil sodium profile page.

Summary for ALOCRIL

US Patents:	0
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	43
Patent Applications:	3,621
Drug Prices:	Drug price information for ALOCRIL
What excipients (inactive ingredients) are in ALOCRIL?	ALOCRIL excipients list
DailyMed Link:	ALOCRIL at DailyMed

See drug prices for ALOCRIL

Pharmacology for ALOCRIL

Drug Class	Mast Cell Stabilizer
Physiological Effect	Decreased Histamine Release

US Patents and Regulatory Information for ALOCRIL

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Allergan	ALOCRIL	nedocromil sodium	SOLUTION/DROPS;OPHTHALMIC	021009-001	Dec 8, 1999		DISCN	Yes	No

Expired US Patents for ALOCRIL

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Allergan	ALOCRIL	nedocromil sodium	SOLUTION/DROPS;OPHTHALMIC	021009-001	Dec 8, 1999	4,474,787
Allergan	ALOCRIL	nedocromil sodium	SOLUTION/DROPS;OPHTHALMIC	021009-001	Dec 8, 1999	RE38628
Allergan	ALOCRIL	nedocromil sodium	SOLUTION/DROPS;OPHTHALMIC	021009-001	Dec 8, 1999	4,760,072

International Patents for ALOCRIL

See the table below for patents covering ALOCRIL around the world.

Country	Patent Number	Title	Estimated Expiration
European Patent Office	0555718
Finland	70899
Israel	84893	PHARMACEUTICAL COMPOSITIONS CONTAINING NEDOCROMIL IN SOLUTION,AND THEIR PREPARATION
Israel	74883	SOLID NEDOCROMIL SODIUM CONTAINING BOUND WATER AND ITS PREPARATION

ALOCRIL Market Analysis and Financial Projection Experimental

Market Dynamics and Financial Trajectory for Alocril

Introduction to Alocril

Alocril, also known as nedocromil ophthalmic solution, is a mast cell stabilizer used in the treatment of allergic conjunctivitis. It is one of the key drugs in the conjunctivitis treatment market, particularly noted for its multiple actions in stabilizing and preventing the actions associated with eosinophils and neutrophils, and preventing the secretion of inflammatory mediators by other surface cells[1].

Market Segmentation and Positioning

Alocril falls under the anti-allergic segment of the conjunctivitis treatment market, which is expected to grow at a faster pace during the forecast period of 2020-2027. This segment contributed to the highest revenue generation in 2019 and is anticipated to register the highest CAGR due to the increased usage of these drugs in treating allergic conjunctivitis[1].

Key Market Drivers

• Rising Prevalence of Allergic Conjunctivitis: The increasing prevalence of allergic conjunctivitis is a significant driver for the market growth. As more patients seek treatment, the demand for effective anti-allergic drugs like Alocril is expected to rise[1][4].
• Technological Advancements: Rapid technological advancements in drug delivery systems and the launch of new, sophisticated products are also driving the market forward. Alocril, being a dual-action drug, benefits from these advancements[1].
• Patient Preference and Convenience: The growing preference for convenient and effective treatments, especially through online pharmacies, is another factor contributing to the market growth. Online pharmacies offer easy availability and convenience, which can boost the sales of Alocril[1].

Market Restraints

• Adverse Effects of Drugs: Despite its benefits, the market for Alocril and similar drugs faces challenges due to the adverse effects associated with some conjunctivitis treatments. This can lead to a decrease in patient compliance and overall market growth[1].
• Patent Expiration: The expiration of patents for key drugs can lead to the launch of generic alternatives, which can impede the growth of branded drugs like Alocril. For instance, the patent expiration of drugs like Pataday and Patanol has impacted the market significantly[1].
• Stringent FDA Approvals: The stringent approval process by regulatory bodies such as the FDA can also restrict market growth. For example, the FDA's decline of the approval for EM-100 by Eton Pharmaceuticals in 2019 highlights the regulatory challenges faced by new and existing drugs[1].

Financial Performance and Projections

• Revenue Contribution: Alocril, as part of the anti-allergic segment, contributes significantly to the revenue of its manufacturer. The global conjunctivitis treatment market was valued at $3.85 billion in 2019 and is projected to reach $4.38 billion by 2027, growing at a CAGR of 3.7% during the forecast period[1].
• Company Performance: Allergan, the manufacturer of Alocril, has a strong presence in the conjunctivitis treatment market. The company's diverse product portfolio, including Alocril, has helped it maintain a leading position in the market. For instance, in 2002, Allergan's pharmaceutical-only businesses saw a significant growth, with sales increasing by 22% in local currencies and earnings per share growing by 27% on a full-year comparable pro forma basis[2].

Competitive Landscape

• Market Leaders: Allergan and Alcon are among the key players dominating the conjunctivitis treatment market. Allergan's strong product portfolio, including Alocril, LASTACAFT, and others, positions it as a market leader. Other players like Novartis AG also contribute to the competitive landscape[1].
• Product Differentiation: Alocril's unique mechanism of action, which includes stabilizing and preventing the actions associated with eosinophils and neutrophils, sets it apart from other treatments. This differentiation is crucial in a market where patients often seek effective and safe treatments[1].

Distribution Channels

• Hospital Pharmacies: Hospital pharmacies are expected to dominate the market in the near future due to an increase in patient visits for regular eye check-ups. However, online pharmacies are also emerging as a significant distribution channel due to patient preference for convenience and easy availability[1].
• Retail Pharmacies: Retail pharmacies and drug stores are expected to hold the lowest market share but still play a vital role in the distribution of Alocril and other conjunctivitis treatments[1].

Regional Analysis

• North America: North America, particularly the United States, dominates the conjunctivitis treatment market, including the segment for allergic conjunctivitis. This region is expected to continue its dominance due to high awareness and advanced healthcare infrastructure[1][4].

Future Outlook

• Emerging Therapies: The dynamics of the allergic conjunctivitis market are expected to change with the launch of emerging therapies. Companies developing future pipeline products need to have novel mechanisms of action and show significant overall efficacy benefits over current standard-of-care treatments[4].
• Awareness and Education: An increase in awareness about allergic conjunctivitis among patients, medical communities, and the general public is expected to drive the growth of the global allergic conjunctivitis market, benefiting drugs like Alocril[4].

Key Takeaways

• Alocril is a key player in the anti-allergic segment of the conjunctivitis treatment market.
• The market is driven by the rising prevalence of allergic conjunctivitis and technological advancements.
• Adverse effects of drugs, patent expirations, and stringent FDA approvals are significant restraints.
• Allergan's strong product portfolio, including Alocril, positions it as a market leader.
• The market is expected to grow at a CAGR of 3.7% from 2020 to 2027.

FAQs

Q: What is Alocril used for? Alocril is used for the treatment of allergic conjunctivitis. It acts as a mast cell stabilizer, preventing the actions associated with eosinophils and neutrophils and the secretion of inflammatory mediators[1].

Q: Who is the manufacturer of Alocril? Alocril is manufactured by Allergan, a leading company in the conjunctivitis treatment market[1].

Q: What are the key drivers of the market for Alocril? The key drivers include the rising prevalence of allergic conjunctivitis, technological advancements in drug delivery, and patient preference for convenient and effective treatments[1][4].

Q: What are the major restraints for the market growth of Alocril? The major restraints include adverse effects of drugs, patent expirations, and stringent FDA approvals[1].

Q: How is the market for Alocril expected to grow in the future? The market is expected to grow at a CAGR of 3.7% from 2020 to 2027, driven by emerging therapies and increased awareness about allergic conjunctivitis[1][4].

Cited Sources

1. Fortune Business Insights: Conjunctivitis Treatment Market Size, Share, Growth | Forecast [2027]
2. Annual Reports: A Growing Focus - Annual Reports
3. DelveInsight: Global Allergic Conjunctivitis Therapy Market and Pipeline Analysis
4. Annual Reports: Reaching further. Living better. - Annual Reports